Contact
ChemoCentryx
Medicines in Motion: Molecular therapy treating autoimmune diseases, inflammatory disorders and cancer
In August 2006, GSK and ChemoCentryx announced a worldwide multi-target strategic alliance to discover, develop and market novel medicines targeting four chemokine and chemoattractant receptors for the treatment of a variety of inflammatory disorders. This alliance with the world's chemokine experts is fully aligned to the ceedd's strategy to seek out and collaborate with companies developing leading-edge science and has resulted in access to selected targets from one of the broadest pipelines of chemokine-based therapeutics in the biopharmaceutical industry.
"GSK's ceedd structure unifies the strengths of both partners...We believe this is a successful deal structure coming of age."
Thomas J. Schall, Ph.D
Chief Executive Officer, ChemoCentryx